Anakinra for Difficult-to-Treat Neutrophilic Panniculitis: IL-1 Blockade as a Promising Treatment Option for Neutrophil-Mediated Inflammatory Skin Disease

Dermatology ◽  
2010 ◽  
Vol 220 (3) ◽  
pp. 264-267 ◽  
Author(s):  
Dan Lipsker ◽  
Cécile Perrigouard ◽  
Audrey Foubert ◽  
Bernard Cribier
Keyword(s):  
Treatment Option ◽  
Skin Disease ◽  
Inflammatory Skin Disease ◽  
Promising Treatment ◽  
Inflammatory Skin

scholarly journals A Case of Exfoliative Vesiculobullous Prurigo Pigmentosa Cured by Doxycycline and Topical Tacrolimus

2021 ◽  
pp. 474-480
Author(s):  
Hoon Choi ◽  
Choong Jae Kim ◽  
Chan Ho Na ◽  
Bong Seok Shin ◽  
Min Sung Kim
Keyword(s):  
Treatment Option ◽  
Skin Disease ◽  
Histological Study ◽  
Clinical Findings ◽  
Inflammatory Skin Disease ◽  
Tacrolimus Ointment ◽  
Safe Treatment ◽  
Topical Tacrolimus ◽  
Inflammatory Skin ◽  
Safe Treatment Option

Prurigo pigmentosa is a rare inflammatory skin disease characterized by an unexpected onset of diffuse erythematous papules and macules usually on the chest, neck, and back. These generally resolve, leaving reticular hyperpigmentation. Rarely, vesicular or bullous forms have been reported. We present a case of exfoliative vesiculobullous prurigo pigmentosa in a 13-year-old boy. He presented with symmetrical eruption of papules and vesicles on his back, neck, and chest in the last 10 days, causing pruritis and prickling sensation. Within a few days, the bullous lesions and all affected areas of the skin showed exfoliation. Histological study and clinical findings indicated the condition to be vesiculobullous prurigo pigmentosa with exfoliation. Treatment with doxycycline 200 mg/day and topical tacrolimus ointment showed a good response. The lesions resolved, leaving a light-brown reticulated hyperpigmentation. In conclusion, this was a case of exfoliative vesiculobullous prurigo pigmentosa in an adolescent man successfully treated with doxycycline and topical tacrolimus as an effective and safe treatment option.

Changes in CD44 isoform expression during inflammatory skin disease

1997 ◽  
Vol 22 (03) ◽  
pp. 128-133
Author(s):  
A.J. HARRIS ◽  
D. DEAN ◽  
S. BURGE ◽  
F. WOJNAROWSKA
Keyword(s):  
Skin Disease ◽  
Inflammatory Skin Disease ◽  
Inflammatory Skin ◽  
Isoform Expression

Chronic Systemic Inflammatory Skin Disease as a Risk Factor for Cardiovascular Disease

2021 ◽  
Vol 46 (5) ◽  
pp. 100799
Author(s):  
David A. Bulger ◽  
Sheharyar Minhas ◽  
Abdul Aziz Asbeutah ◽  
Sharif Kayali ◽  
Hamid A.K. Shirwany ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Skin Disease ◽  
Inflammatory Skin Disease ◽  
Inflammatory Skin

scholarly journals Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab

2016 ◽  
Vol 10 (1) ◽  
pp. 92-98 ◽  
Author(s):  
Glenn Harvin ◽  
George Kasarala
Keyword(s):  
Tumor Necrosis Factor ◽  
Skin Disease ◽  
Hidradenitis Suppurativa ◽  
Tumor Necrosis ◽  
Tnf Inhibitors ◽  
Tnf Inhibitor ◽  
Inflammatory Skin Disease ◽  
Inflammatory Skin ◽  
Necrosis Factor ◽  
Inhibitor Treatment

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by recurring abscesses, nodules, and fistulas predominantly in the groin and axillae. The association between HS and Crohn’s disease (CD) has been well documented. Tumor necrosis factor (TNF) inhibitors have shown to be effective in treating both HS and CD. We report 2 patients who developed HS while on TNF inhibitor treatment for CD.

Sign in / Sign up

Export Citation Format

Share Document